Status: Recruiting
Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL
To evaluate orelabrutinib in combination with polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) as first-line treatment for patients with intermediate- to high-risk diffuse large B-cell lymphoma (DLBCL).
Participants needed: 30
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: The First Affiliated Hospital of Xiamen UniversityUpdated: Aug 21, 2026Locations: 2
Eligibility criteria
Aged ≥ 18 years; [+6]
Lymphoma involving the central nervous system or leptomeningeal metastasis; [+15]